Loading
A phase 2 trial of Pembrolizumab, Lenvatinib in vulvar cancer, run by AGO Research GmbH, now recruiting.
Pembrolizumab Combination With Lenvatinib in Pts With Recurrent,Persistent,Metastatic or Locally Advanced Vulvar Cancer Not Amenable to Curative Surgery or Radiotherapy is a phase 2 interventional study registered as NCT05903833 by AGO Research GmbH, with 42 participants planned, started 2025-06-24 and due to reach its primary completion in 2027-10-30. Interventions recorded: Pembrolizumab, Lenvatinib. Conditions listed: Recurrent Vulvar Cancer, Persistent Vulvar Cancer, Metastatic Vulva Cancer, Locally Advanced Vulvar Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Lenvatinib, Anti-angiogenic therapy, Pembrolizumab, Small-molecule kinase inhibitors.
Shares HPV-independent vulvar squamous cell carcinoma (p53-mutant), HPV-associated vulvar squamous cell carcinoma, Vulvar cancer, Immune checkpoint inhibitors.
Shares Lenvatinib, Anti-angiogenic therapy, Pembrolizumab, Small-molecule kinase inhibitors.
Shares Lenvatinib, Anti-angiogenic therapy, Pembrolizumab, Small-molecule kinase inhibitors.
Shares Lenvatinib, Anti-angiogenic therapy, Pembrolizumab, Small-molecule kinase inhibitors.
Shares HPV-independent vulvar squamous cell carcinoma (p53-mutant), HPV-associated vulvar squamous cell carcinoma, Vulvar cancer.
Shares Lenvatinib, Anti-angiogenic therapy, Pembrolizumab, Small-molecule kinase inhibitors.
Shares HPV-independent vulvar squamous cell carcinoma (p53-mutant), HPV-associated vulvar squamous cell carcinoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/